Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study

OBJECTIVE: To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate COVID-19. METHODS: In this phase 2, randomized, open-label study, adult subjects aged ≥18 years with RT-PCR confirmed COVID-19 with moderate sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandit, Anuja, Bhalani, Nirav, Bhushan, B.L. Shashi, Koradia, Parshottam, Gargiya, Shweta, Bhomia, Vinay, Kansagra, Kevinkumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944859/
https://www.ncbi.nlm.nih.gov/pubmed/33713817
http://dx.doi.org/10.1016/j.ijid.2021.03.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944859/
https://www.ncbi.nlm.nih.gov/pubmed/33713817
http://dx.doi.org/10.1016/j.ijid.2021.03.015

Ejemplares similares